Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and commercialize next-generation pneumococcal conjugate vaccines (PCVs) for treating ...

In June, Merck’s 21-valent Capvaxive became the first pneumococcal vaccine specifically designed for adults to receive FDA approval. Then, in September, Vaxcyte unveiled what analysts called ...

Merck MRK also markets two PCV vaccines — Capvaxive and Vaxneuvance. MRK received FDA approval for Vaxneuvance in 2021 for 15 serotypes in older adults. Merck generated $647 million from ...

Merck's DOR/ISL regimen demonstrated non-inferiority to bART and BIC/FTC/TAF in two pivotal Phase 3 trials for adults with HIV-1. Both trials achieved primary safety objectives, with detailed ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion. Under the terms of the deal, the company will gain the exclusive global ...

Merck’s new 21-valent pneumococcal conjugate vaccine, Capvaxive, and pulmonary arterial hypertension drug, Winrevair, have the potential to generate significant revenues for Merck over the long ...

Merck (NYSE:MRK) and Chinese biopharmaceutical company Hansoh Pharma (OTCPK:HNSPF) announced a global licensing deal on Wednesday to develop HS-10535, an oral GLP-1 receptor agonist targeted at ...

Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion. Merck will pay Hansoh $112 million ...

Earlier this week, Merck MRK announced that it is discontinuing the development of two of its cancer candidates, vibostolimab and favezelimab. Merck was separately studying vibostolimab and ...

In recent months, Merck has made notable strides in expanding its product offerings. The company received FDA approval for CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine (PCV) for adults, ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a preclinical drug. The Big Pharma already has efinopegdutide, a dual GLP-1 ...